Education
About Us
Working with TipRanks
Follow Us
Camurus AB (CAMRF)
OTHER OTC:CAMRF
CAMRF Stock Chart & Stats
Day’s Range― - ―
52-Week Range$46.15 - $73.75
Previous CloseN/A
Volume89.00
Average Volume (3M)49.00
Market Cap
$3.82B
Enterprise Value$13.37B
Total Cash (Recent Filing)$2.85B
Total Debt (Recent Filing)kr17.04M
Price to Earnings (P/E)72.5
Beta0.74
Next Earnings
Jul 17, 2025EPS Estimate
0.35Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.35
Shares Outstanding59,626,984
10 Day Avg. Volume10
30 Day Avg. Volume49
Financial Highlights & Ratios
PEG Ratio-1.56
Price to Book (P/B)13.98
Price to Sales (P/S)0.00
P/FCF Ratio140.09
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$66.72Price Target Upside4.87% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering0
Camurus AB News
PremiumCompany Announcements
Camurus’ POSITANO Study Shows Promising Results for PLD Treatment
PremiumCompany Announcements
Camurus Partners with Eli Lilly for Long-Acting Incretin Therapies
PremiumCompany Announcements
Camurus Executes Share Repurchase to Support Incentive Plan
PremiumCompany Announcements
Camurus AB Reports Strong Q1 2025 FinancialsPremiumCompany Announcements
Camurus Reports Strong Q1 2025 Performance with Significant Revenue Growth
PremiumCompany Announcements
Camurus Appoints New CFO to Drive Growth and DiversificationOptions Prices
Currently, No data available
---
Ownership Overview
―
Insiders
4.41% Mutual Funds
― Other Institutional Investors
93.10% Public Companies and
Individual Investors
CAMRF FAQ
What was Camurus AB’s price range in the past 12 months?
Camurus AB lowest stock price was $46.15 and its highest was $73.75 in the past 12 months.
What is Camurus AB’s market cap?
Camurus AB’s market cap is $3.82B.
When is Camurus AB’s upcoming earnings report date?
Camurus AB’s upcoming earnings report date is Jul 17, 2025 which is in 17 days.
How were Camurus AB’s earnings last quarter?
Camurus AB released its earnings results on May 15, 2025. The company reported $0.354 earnings per share for the quarter, beating the consensus estimate of $0.308 by $0.046.
Is Camurus AB overvalued?
According to Wall Street analysts Camurus AB’s price is currently Undervalued.
Does Camurus AB pay dividends?
Camurus AB does not currently pay dividends.
What is Camurus AB’s EPS estimate?
Camurus AB’s EPS estimate is 0.35.
How many shares outstanding does Camurus AB have?
Camurus AB has 59,626,984 shares outstanding.
What happened to Camurus AB’s price movement after its last earnings report?
Camurus AB reported an EPS of $0.354 in its last earnings report, beating expectations of $0.308. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Camurus AB?
Currently, no hedge funds are holding shares in CAMRF
Company Description
Camurus AB
Camurus AB (publ), a pharmaceutical company, develops and commercializes medicines for severe and chronic conditions in Europe, Australia, the United States, Japan, and internationally. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence; episil oral liquid, a medical device for the treatment of inflammatory and painful conditions in the oral cavity; and Brixadi to treat opioid use disorder Its products pipeline also includes CAM2038 for the treatment of chronic pain; CAM2029, which is in phase III clinical trials for the treatment of acromegaly and neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 that is in phase I clinical trial for the treatment of pulmonary arterial hypertension, as well as in Phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; CAM2047 for the treatment of chemotherapy-induced nausea and vomiting that is in phase 1 clinical trial; and CAM2048, which is in phase I clinical trial for postoperative pain. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
CAMRF Company Deck
CAMRF Earnings Call
Q1 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented strong financial performance and growth in key product sales, along with a solid cash position. However, challenges such as the FDA's CRL and increased operating expenses were noted. The positive aspects of growth and profitability were more pronounced, leading to an optimistic outlook.Read More>Technical Analysis
Hansa Biopharma AB
―
BioArctic AB Class B
―
SynAct Pharma AB
―
Xbrane Biopharma AB
―
Xspray Pharma AB
―